Johnson & Johnson single-dose vaccine shown to be effective against COVID-19

Johnson & Johnson single-dose vaccine shown to be effective against COVID-19

But the positive news was offset by results that showed the vaccine, called NVX-CoV2373, was much less effective against a variant of the coronavirus first identified in South Africa that is spreading quickly around the world.

The Tánaiste said the "particularly encouraging" aspect of the Johnson and Johnson vaccine is that it is administered in a single dose, and he expects the company to apply for approval in the European Union in March with the rollout beginning in April.

USA biotech firm Novavax said Thursday its two-shot COVID-19 vaccine candidate showed 89.3 percent efficacy in a major phase-3 clinical trial in Britain.

J&J said on Friday that in the U.S. and seven other countries, the single-shot vaccine was 66 per cent per cent effective overall at preventing moderate to severe illness.

An global trial looked at giving just one dose of the vaccine, which makes it significantly easier to roll out than those requiring two.

However, it reported lower efficacy in South Africa, where a new variant of the virus has emerged.

Moderna, a US biotechnology company, said earlier this week that its vaccine is expected to be protective against the variants, but that it is advancing a vaccine booster candidate against the South African strain into preclinical studies.

Johnson & Johnson said Friday that its COVID-19 vaccine is effective at stopping the virus, but less effective against variants.

The United States found its first cases of the coronavirus variant first detected in South Africa in SC this week. It proved to be 60% effective among volunteers who didn't have HIV.

Of the participants, 44% were from the USA, 41% from Central and South America, and 15% from South Africa.

BMW M5 CS revealed
German automobile giant BMW introduced the 2022 BMW M5 C5 sedan, which they call the fastest BMW to date. A light fixed cover on the center console replaces the usual armrest with an opening cover.

While it released few details, the company said there were no serious allergic reactions.

Rival AstraZeneca makes a similar cold virus vaccine that requires two doses.

As of Day 28, injection also offered "complete protection" from Covid-19 hospitalisation and death.

U.S. President Joe Biden has promised that at least 100 million shots will be administered in his first 100 days in office, but concerns about supply disruptions have added uncertainty to that target.

With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.

The UK has already pre-ordered 30m doses.

J&J has said it plans to deliver 1 billion doses in 2021 and will produce the vaccine in the United States, Europe, South Africa and India.

Novavax is also discussing with the FDA whether its data is sufficient to apply for emergency use authorization.

J&J said its vaccine works consistently in a broad range of people.

Related Articles